Additional file 2: Table S1. of Diversity and distribution of alpha satellite DNA in the genome of an Old World monkey: Cercopithecus solatus

Filtering steps from Cercopithecus solatus raw data to alpha satellite monomer and dimer datasets. Table S2. Alpha satellite family associations in Cercopithecus solatus dimer dataset. (DOCX 40 kb

Additional file 3: Text S1. of Diversity and distribution of alpha satellite DNA in the genome of an Old World monkey: Cercopithecus solatus

Alignment used to generate the phylogenetic tree from Fig. 7a. (TXT 28 kb

Additional file 4: Text S2. of Diversity and distribution of alpha satellite DNA in the genome of an Old World monkey: Cercopithecus solatus

Alignment used to generate the phylogenetic tree from Fig. 7b. (TXT 48 kb

Associations between genetic polymorphisms and occurrence of CNV.

<p>CI: confidence interval; CNV: choroidal neovessels; HR: Hazard ratio.</p><p>^aCox model adjusted for age, gender and treatment. Each variant was introduced in separate model.</p><p>^bModel 2: Cox model adjusted for age, gender, treatment, BMI, smoking, HDL, triglycerides, genetic polymorphisms of <i>ARMS2</i> A69S or <i>CFH</i> Y402H.</p><p>^cGlobal p-value was obtained using the genotype of the variant as a continuous variable according to the number of risk allele.</p><p>Associations between genetic polymorphisms and occurrence of CNV.</p

<i>CFH</i> Y402H and <i>ARMS2</i> A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study

<div><p>Purpose</p><p>Genetic susceptibility could be modified by environmental factors and may also influence differential responses to treatments for age-related macular degeneration (AMD). We investigated whether genotype could influence response to docosahexaenoic acid (DHA)-supplementation in the occurrence of choroidal new vessels (CNV).</p><p>Methods</p><p>The Nutritional AMD Treatment 2 (NAT2) study was a randomized, placebo-controlled, double-blind, parallel, comparative study, including 250 patients aged 55 to 85 years with early lesions of age-related maculopathy, visual acuity better than 0.4 Logarithm of Minimum Angle of Resolution units in the study eye and neovascular AMD in the fellow eye. Patients were randomized at baseline to receive either 3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E, or placebo.</p><p>Results</p><p>Patients carrying the risk allele (C) for <i>CFH</i> Y402H had no statistically significant increased risk for developing CNV in the study eye (Hazard Ratio (HR)=0.97; 95% Confidence Interval (CI): 0.54-1.76 for heterozygous and HR=1.29; 95%CI: 0.69-2.40 for homozygous). Patients carrying the risk allele (T) for <i>ARMS2</i> A69S had no statistically significant increased risk for developing CNV in the study eye (HR=1.68; 95%CI: 0.91-3.12) for heterozygous and HR=1.78; 95%CI: 0.90-3.52 for homozygous). A significant interaction was observed between <i>CFH</i> Y402H and DHA-supplementation (p=0.01). We showed a protective effect of DHA-supplementation among homozygous non-risk patients. Among these patients, occurrence of CNV was 38.2% in placebo group versus 16.7% in DHA group (p=0.008).</p><p>Conclusions</p><p>These results suggest that a genetic predisposition to AMD conferred by the <i>CFH</i> Y402H variant limits the benefit provided by DHA supplementation.</p><p>Trial Registration</p><p>ISRCTN registry <a href="http://www.isrctn.com/ISRCTN98246501" target="_blank">98246501</a></p></div

Associations between baseline demographic and behavioral characteristics and occurrence of CNV.

<p>NAT2 Study, n = 250, 2003–2005.</p><p>CNV: choroidal neovessels; HDL: high density lipoprotein; LDL: low density lipoprotein; SD: standard deviation.</p><p>^ap for Student’s t test for age, Pearson Chi² test for gender and logistic regression adjusted for age, gender and treatment for other variables.</p><p>Associations between baseline demographic and behavioral characteristics and occurrence of CNV.</p

Variations of EPA+DHA in serum and red blood cells membranes according to <i>CFH</i> Y402H and <i>ARMS2</i> A69S at baseline and after 3 years DHA supplementation.

<p>NAT2 Study, n = 250, 2003–2005.</p><p>RBCM: red blood cells membranes.</p><p>Variations of EPA+DHA in serum and red blood cells membranes according to <i>CFH</i> Y402H and <i>ARMS2</i> A69S at baseline and after 3 years DHA supplementation.</p

Diagram showing the population of Nutritional AMD Treatment 2 Study design included in this paper.

<p>Full analysis set (FAS) included patients having at least one post baseline value regarding occurrence of CNV. AMD: age-related macular degeneration; CNV: choroidal neovascularization; DHA: docosahexaenoic acid.</p